Please use this identifier to cite or link to this item:
|Title:||Polymorphisms associated with everolimus pharmacokinetics, toxicity and survival in metastatic breast cancer.|
Polymorphism, Single Nucleotide
|Abstract:||Metastatic breast cancer (MBC) progressing after endocrine therapy frequently activates PI3K/AKT/mTOR pathway. The BOLERO-2 trial showed that everolimus-exemestane achieves increased progression free survival (PFS) compared with exemestane. However, there is great inter-patient variability in toxicity and response to exemestane-everolimus treatment. The objective of this study was to perform an exploratory study analyzing the implication of single nucleotide polymorphisms (SNPs) on outcomes from this treatment through a pharmacogenetic analysis.|
|Appears in Collections:||Hospitales > H. U. 12 de Octubre > Artículos|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.